Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis

K. E. Piper, M. S. Rouse, K. L. Ronningen, J. M. Steckelberg, W. R. Wilson, R. Patel

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The activity of trovafloxacin was compared with those of vancomycin and penicillin in a model of Streptococcus sanguis species group (trovafloxacin MIC, 0.125 μg/ml) and Streptococcus mitis species group (trovafloxacin MIC, 0.125 μg/ml) experimental endocarditis. Rabbits with catheter-induced aortic valve vegetations were given no treatment, trovafloxacin at 15 mg/kg of body weight three times a day (t.i.d.), vancomycin at 15 mg/kg twice a day, or penicillin at 1.2 x 106 IU t.i.d. After 3 days of treatment, the animals were sacrificed; cardiac valve vegetations were aseptically removed and cultured quantitatively. Penicillin was as active as vancomycin as measured by in vivo clearance of bacteria. Trovafloxacin was less active (P < 0.05) than vancomycin or penicillin against S. sanguis species group infection but had similar efficacy against S. mitis species group infection. Quinolones, despite MICs in the susceptible range, may not be active for serious infections caused by some viridans group streptococci.

Original languageEnglish (US)
Pages (from-to)2554-2556
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Issue number9
StatePublished - 2000

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis'. Together they form a unique fingerprint.

Cite this